Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

DOI10.1111/j.1365-2125.2011.04037.xWikidataQ35629751 ScholiaQ35629751MaRDI QIDQ5977801

Jean‐Louis Montastruc, Agnès Sommet, Haleh Bagheri, Maryse Lapeyre‐Mestre

Publication date: 9 November 2011

Published in: British Journal of Clinical Pharmacology (Search for Journal in Brave)

Related Items

pvda